GT
DRNA

Glenmede Trust’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Glenmede Trust’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,575
Closed -$469K – 1361
2021
Q2 		$469K Sell
12,575
-938
-7% -$28.8K ﹤0.01% 911
2021
Q1 		$345K Buy
13,513
+223
+2% +$5.7K ﹤0.01% 946
2020
Q4 		$291K Buy
13,290
+1,300
+11% +$28.6K ﹤0.01% 971
2020
Q3 		$215K Buy
11,990
+2,905
+32% +$60.1K ﹤0.01% 1009
2020
Q2 		$230K Buy
9,085
+2,230
+33% +$48K ﹤0.01% 973
2020
Q1 		$151K Hold
6,855
– – ﹤0.01% 1291
2019
Q4 		$151K Buy
+6,855
New +$138K ﹤0.01% 1291

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Glenmede Trust's DRNA Position: Q3 2021 in Review

Glenmede Trust sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 12,575 shares — an estimated $469K sold.

Glenmede Trust first reported a position in DRNA in Q4 2019 and held it in 7 quarters. The position peaked at $469K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Glenmede Trust reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Glenmede Trust sold 12,575 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $469K.
  • Glenmede Trust first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 7 quarters.
  • Glenmede Trust's Dicerna Pharmaceuticals, Inc. position peaked at $469K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Glenmede Trust's 13F filing for Q3 2021, filed 15 Nov 2021.